Jaguar Health, Inc. (JAGX) stock
Close on Nov 12, 2026Market cap $2.07MP/E –Yield –
Jaguar Health, Inc. grew revenue 135.5% to $27.82M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $2.07M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.07M
- P/E ratio
- –
- Price to sales
- 0.07
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $27.82M
- Net income
- -$53.58M
- EPS, diluted
- -$22.97
- Diluted shares
- 1M
Trading
- Previous close
- $0.48
- Open
- $0.47
- Day's range
- $0.38 – $0.47
- Volume
- 946,323
- Average volume (20 days)
- 915,452
- Beta (5 years)
- 2.17
- 52-week range
- $0.36 – $1039.50
- RSI (14 days)
- 36.2
- Volatility (1 year)
- 1210.3%
- Relative volume
- 0.57×
- WACC
- 14.1%
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | JAGX | S&P 500 | Difference | JAGX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -91.4% | -2.7% | −88.7 pts | ||
| 3 months | -96.5% | -1.7% | −94.7 pts | ||
| Year to date | -99.9% | +11.9% | −111.8 pts | ||
| 1 year | -100.0% | +12.0% | −111.9 pts | ||
| 3 years | -100.0% | +78.2% | −178.2 pts | -98.8% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -98.0% | +11.6% |
| 10 years | -100.0% | +309.6% | −409.6 pts | -93.2% | +15.1% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Jaguar Health filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Results
- News
About Jaguar Health
Pharmaceutical Preparations
The company operates in the pharmaceutical industry and focuses on developing and commercializing therapeutic products. Its business activities are organized into two primary operating segments: Human Health and Animal Health. The company develops and markets treatments such as Mytesi, Gelclair, Neonorm, and Canalevia. Key customers for its product offerings include specialized healthcare purchasers such as specialty pharmacies and pharmaceutical distributors.
Company profile, executives and historyJaguar Health stock: common questions
What is Jaguar Health's stock price?
JAGX closed at $0.40 on Nov 12, 2026, down 16.67% on the day. Over the past 52 weeks it traded between $0.36 and $1039.50.
What is Jaguar Health's market cap?
Jaguar Health was worth $2.07M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is JAGX's P/E ratio?
Jaguar Health lost money over fiscal 2025 (diluted EPS -$22.97), so it has no meaningful P/E ratio.
How much revenue does Jaguar Health make?
Jaguar Health reported revenue of $27.82M for the twelve months to Jun 30, 2026, up 135.5% from a year earlier.
Does Jaguar Health pay a dividend?
No. Jaguar Health has not paid a cash dividend over the last twelve months.
How has JAGX stock performed over the past year?
Including dividends, JAGX returned -100.0% over the past year, against +12.0% for the S&P 500.
How many JAGX shares are sold short?
0M shares were sold short at the latest FINRA report, 4.69% of the float, or 1.0 days of average trading volume.
Who are Jaguar Health's competitors?
Companies most similar to Jaguar Health by business, industry and size include BHST, ZOMDF, MCUJF, CELU, EMMA.
See a number that looks wrong?